They're apples and oranges. Cant really compare between the two. Sure it's nice to help humankind and fight diseases and all that. chances are the herpes drug is probably going to fail plus being preclinical and phase one you're easily looking at a 7-10 year timeline. The costs are astronomical, if anything I would prefer if they focused on producing what they do best such as cardiocell and collagen scaffolding. On what you're saying about market, the problem with surgeries is that you need surgeons to take up these procedures and that takes time. With APAS, you just need major corporations such as SHL to take it up and you're already ahead with a massive market share. I'm not saying that AHZ or LBT is better, they're different and unlike what you say, they both actually help humankind considerably. With time though, cardiocell and vascucell would be greatly taken up but it takes time.
- Forums
- ASX - By Stock
- AVR
- Will tomorrow see 55c?
Will tomorrow see 55c?, page-39
-
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$10.00 |
Change
0.000(0.00%) |
Mkt cap ! $211.3M |
Open | High | Low | Value | Volume |
$10.00 | $10.00 | $10.00 | $1.33K | 133 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 749 | $9.82 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$10.00 | 3796 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 9.860 |
2 | 4587 | 9.800 |
1 | 200 | 9.600 |
1 | 2 | 9.540 |
2 | 280 | 9.500 |
Price($) | Vol. | No. |
---|---|---|
10.000 | 2758 | 1 |
10.490 | 198 | 1 |
11.500 | 250 | 1 |
12.000 | 5000 | 1 |
12.500 | 560 | 1 |
Last trade - 10.00am 11/11/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
3DA
AMAERO INTERNATIONAL LTD
Hank Holland, Executive Chairman and CEO
Hank Holland
Executive Chairman and CEO
SPONSORED BY The Market Online